Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

NCT03883412 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether exercise, the medication liraglutide, or both together can improve blood vessel function and insulin sensitivity in adults with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 21–60 · all sexes Healthy volunteers accepted.

Timeline Started 2019-02 · est. completion 2025-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03883412 ↗

Description as written by the study sponsor.

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Treatments tested

Exercise Other

16 weeks of treatment
Liraglutide Drug

16 weeks of Liraglutide

Main thing measured	Microvascular Blood Volume - change from baseline
Sponsor	University of Virginia
Conditions studied	Type2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03883412 ↗